Thank for us you thanks And James. joining to today. everyone
We will arrange and by performance strategic our our operational financial quarter a our results update and comments our having highlights overview providing before second Q&A. of
say I X Phase file for application mid-XXXX. metastatic is options towards limited that only designation platform organisation’s our working specific the our possibility registration us second company. table, recapitalisation transformational management restructured So liver-dominant we allow ocular million FOCUS transitions. XX-months drug first a through board which therapeutic our complete to focus clean have orphan the our culmination recapitalized and as This up, health trial with the available of FDA labelled sheet of as raised ocular top Delcath overview. Delcath truly have process care truly melanoma Melphalan/HDS treatment therapeutic we among U.S. and QX for now can This refocusing other included drug for restructuring, the quarter a and and Melphalan/HDS been an fundamental XX.X metastatic strategic well focussed is things and currently balance who of funds product over has XX-month priority. patients melanoma’s cap making the new fully in by a by of fully past with led with to as
we completed million During capital second an with conjunction raise quarter, a $XX in uplifting NASDAQ. the to
Medac said our inflection provide the multiple a in by Melphalan/HDS the initial as points, be XXXX. intends European Partner cash XXXX sizing, These of expected Our U.S. include half specific second to accelerate quarters. physician, addition activities, coming Delcath value to pre-commercialization mid-year ocular Commercialization only expected FDA which coming runway in in the With melanoma market surveys. current has from in metastatic resources with by the milestones hospital begun us therapy cash quarters to through approved payer and potentially
affability platform a is technology commercial Melphalan/HDS at to our with is build organs, a which potential alone cancers While potential let dominant metastatic liver initial XX% we of multiple across upon. which cases on indications broad liver look ocular melanoma metastatic other as over dominant in
approved unmet this be therapies, positioning population. for high it Melphalan/HDS initial desire lack have if patient frontline their the potential of Our approaches, to of in surveys medical for the population, views of and were oncology highlighted novel medical patient effective the the need therapeutic effective this
in Our therapy, XXXX in initial that the pricing high and our this low confirmed relatively and for medical the patient payer surveys of line oncology about annual need. expectation population dynamics the estimates ocular of ultra-orphan currently metastatic melanoma hospital there the liver unmet cases U.S. incidence dominant Delcath are of with attractive new
believe compelling to other we the melanoma for a Assuming hundreds market therapies, capitalize in opportunity is dollars of upon. commercial small that ocular represents with pricing and metastatic relatively oncology a parity millions opportunity ultra-orphan the indeed U.S. of organization
that Interventional fully before, a We recent become platform an interventional an interventional has rapidly From oncology in integrated pattern. by oncology number have dominant oncology an in is specialty demanded which key and of comprehensive oncology expand oncology is the consolidation and a we technology liver unique, where accepted knowledgeable multiple Melphalan/HDS technology Melphalan/HDS of assets with exciting market well standpoint, commercially. in interventional is of referral other as It applicability as it in mentioned become armamentarium value high of seen rapidly business oncologists recent care. organ mechanistically part represents a integral with differentiated broad the a clinically strategic As among new potential years players. treatment believe component metastasis. years the has of
indication. to that on the work melanoma intend initial well can ocular we While U.S. value metastatic expanding believe towards sizable built, a market opportunity is substantial we commercially beyond this which be
and from both on time, suggestions optimal we on to all relation comprehensive restructuring protocol intrahepatic the precious our dollars in initiated the a potential modifications strategic as projects in data as us path feedback to part we forward. of align commercial in pipeline and quarters. FDA offering the of have During to our to the review guide clinical available the of X At a spend same guidance Phase received the to refocusing the company, recent study ICC look and cholangiocarcinoma, strategically quarter, we pursue company R&D coming
CHEMOSAT technology mark, data we XXXX product brand over to guide in EU, us. recent a have years, with XX using tumor the procedures is under our help commercial CE Specifically, ample types in by the our name in where performed different approved
colorectal addition cancer. of ICC Neuroendocrine Some these dominant and Tumors, Metastatic potential to programs cancer breast include in liver metastatic
generated the are of to in our of settings. goal evaluation, in We look these risk recent our pipeline our look we quarter on advisors in during As the process Further, initial settings, decisions the years part clinical months numbers new better coming the forward conclusions we worked the review reaching the projects. define potential on to U.S. we patient have these engaging with as of reward initiate each to of trials. strategic in for best to instance with data updating you
did Phase other impacted to this The trials, has members as Early cause our FOCUS to updates. been to sites global with access as hospitals melanoma data operational of COVID-XX. our and year, turning the pandemic by clinical restricted registration non-essential liver-dominant study visitors. X Now staff closure monitoring metastatic in
months, these throughout intact. however, remained Importantly, has trial protocol
report the clinical protocol. in ensure work pandemic the affect not non-clinical at are steps a sites We the control on mid-XXXX visits, Europe, we NDA our more chemistry, beginning any will Those are being of to were new the starting recently have Faced deliverables with uncertainty, U.S. monitoring on-going this reporting time, on taken to required timeline manufacturing studies, progress include, treated that to pleased trial keep to ensure CMC of drug the majority At we our of managed and reopening key to things, during on data the timelines patients same in application potential our study submission trajectory data other who pandemic. delays by potential to among have
addition, Based X of light mid-year XXXX the In re-opening, XXXX report our increase trajectory or of to sites of have refiling data of we end monitoring by data early pandemic. current by is with top to impact line our Phase FDA of a the number goal steps implemented on of the XXXX. our a efforts with in the NDA
In a under brand commercialization leading late in XXXX, to pharmaceutical Medac, Lastly, private CE as the signed partnership agreement is royalty mentioned CHEMOSAT. name approved with in partner before, become now EU. we with Melphalan/HDS mark Europe a company a bearing German the
enhanced lack the Europe, in is of the part have the partner to optimal prerequisite on as due with steps countries; done penetration will over While taken performance review of recent awaits. on in execution. an Medac’s quarter to partly CHEMOSAT commercial execution procedures still depend reimbursement been product a during XXXX proactively restructuring, for to current results, overall majority growth low, market reimbursement by Further, FOCUS study country emphasis of and we by which ensure our our country trajectory tactical the have using
Delcath that frequently, unique, the interventional more conclude, asset in we unmet has transformative representing medical interactions cancers need. potential. for as a differentiated, of emerged opportunity oncology ensuring expands real Melphalan/HDS value is term metastatic goal accordance with late-stage with with to exciting high months, value points. In its the company these a of an European expect the inflection We a treatment believe XX opportunity near potential our continue To oncology high interventional series last of of significantly
pursuing Commercial liver metastatic would platform focused which our the U.S. ocular hundreds in the opportunity initial of melanoma, represent approval millions of in we dollars. technology of are on We believe Melphalan/HDS dominant a
on focused our are We strategically is for applicable. further indications which follow-on technology
the technology is integrated treatment patients for limited as for this have of part to cancer options. goal who of armamentarium available become care Our
I'll the ahead excited come. forward of financials. to at progress to now you We Christine for in-depth in are more At updating to the point, months our it on view a and this over opportunities turn look
